Our bill has guardrails. It does not give FTC any new power or regulatory authority.
I hope this committee will have the same success voting this bill out.
I believe, like Senator Cruz just said, that the consumer ought to be the point of everything that we are trying to acco...
PBMs are blocking a cheaper product.
It requires the FTC to study pharmaceutical intermediaries and issue a report and recommendations to Congress within one...
The Cantwell-Grassley PBM transparency bill directs the FTC to end well-known and documented PBM practices that drive up...
Any true attempt at understanding the factors driving costs must include a look at the broader supply chain.
FMI thanks Chairwoman Cantwell and Sen. Grassley for championing the PBM Transparency Act.
I've hauled Big Pharma and PBM executives before the Finance Committee.
I worked at the FTC, and I can tell you that with the Agency's overreach and activism, which will no doubt be difficult ...